Le Visage Catherine, Rioux-Leclercq Nathalie, Haller Michael, Breton Pascal, Malavaud Bernard, Leong Kam
Biomedical Engineering Department, The Johns Hopkins School of Medicine, Baltimore, Maryland 21205, USA.
J Urol. 2004 Mar;171(3):1324-9. doi: 10.1097/01.ju.0000103922.12319.59.
We aimed to promote the efficacy of paclitaxel in intracavitary treatment of superficial transitional cell carcinoma of the bladder by designing bio-adhesive microspheres capable of achieving controlled release of the drug at the urothelium/urine interface.
Poly(methylidene malonate 2.1.2) microspheres encapsulating paclitaxel were prepared by a single emulsion method. Bioactivity of the released paclitaxel was confirmed by assessing cytotoxicity on MBT-2, a bladder cancer cell line. Biodistribution of particles after bladder instillation was assessed by confocal microscopy and scanning electron microscopy. In vivo studies were performed in Balb/c mice after bladder cancer was induced by BBN (N-n-Butyl-N-butan-4-ol-nitrosamine) in drinking water. The efficacy of intravesical injections of conventional and microsphere paclitaxel was assessed by histology and survival rates.
Spherical 5 microm microspheres with 5% weight per weight paclitaxel loading ensured sustained release of bioactive paclitaxel. After bladder instillation the microspheres adhered to the mucosa and remained in the bladder lumen for at least 48 hours. In the BBN induced bladder cancer model compared with controls the 9-week survival rate was significantly improved by 2 injections of paclitaxel bio-adhesive microparticles. Microscopic evaluation confirmed the lower incidence of carcinoma in situ and high grade transitional cell carcinoma after injections of paclitaxel bio-adhesive microparticles compared with controls and with injections of similar doses of the conventional paclitaxel formulation.
Intravesical administration of poly(methylidene malonate 2.1.2) paclitaxel microspheres is a promising approach for intracavitary chemotherapy of superficial bladder cancer.
我们旨在通过设计能够在尿路上皮/尿液界面实现药物控释的生物粘附微球,提高紫杉醇在膀胱浅表性移行细胞癌腔内治疗中的疗效。
采用单乳液法制备包裹紫杉醇的聚(亚甲基丙二酸2.1.2)微球。通过评估对膀胱癌细胞系MBT - 2的细胞毒性来确认释放的紫杉醇的生物活性。通过共聚焦显微镜和扫描电子显微镜评估膀胱灌注后颗粒的生物分布。在通过饮用水中添加BBN(N - 正丁基 - N - 丁醇 - 亚硝胺)诱导膀胱癌的Balb/c小鼠中进行体内研究。通过组织学和生存率评估膀胱内注射常规紫杉醇和微球紫杉醇的疗效。
载药量为5%(重量/重量)的5微米球形微球确保了生物活性紫杉醇的持续释放。膀胱灌注后,微球粘附于黏膜并在膀胱腔内至少保留48小时。在BBN诱导的膀胱癌模型中,与对照组相比,两次注射紫杉醇生物粘附微粒可使9周生存率显著提高。显微镜评估证实,与对照组以及注射相似剂量常规紫杉醇制剂相比,注射紫杉醇生物粘附微粒后原位癌和高级别移行细胞癌的发生率更低。
膀胱内给予聚(亚甲基丙二酸2.1.2)紫杉醇微球是浅表性膀胱癌腔内化疗的一种有前景的方法。